Source:

Press Release

March 01, 2021
1 min read
Save

Bio-Tissue pursuing investigational new drug for dry eye treatment

Source:

Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Bio-Tissue can proceed with a phase 2 study investigating morselized cryopreserved amniotic membrane and cryopreserved umbilical cord following clearance from the FDA, according to a press release.

TTBT01 is being studied to support regenerative healing in dry eye disease. Because it is a section 351 biologic investigational new drug, TTBT01 will undergo a strict FDA preapproval process involving two randomized phase 3 clinical trials demonstrating safety and efficacy, the release said.

“Our leadership team determined early on that going after a regenerative therapy based on natural human birth tissue to achieve ocular surface optimization would be the right thing to do — affording the company the opportunity to give physicians optimal treatment options to manage common dry eye problems effectively,” Amy Tseng, president, CEO and co-founder of TissueTech, parent company of Bio-Tissue, said in the release.